BackgroundAutologous conditioned serum is a product of blood origin, with fragmented evidence of therapeutic properties in osteoarthritis chronic pain. This pilot observational prospective study aimed to evaluate the feasibility of a treatment with conditional autologous serum (ACS) in patients with severe chronic pain and grade I-III osteoarthritis and to describe its cytokine content. MethodsWe prospectively collected data on consecutive patients affected by osteoarthritis grade I to III and treated with four weekly injections of ACS at our outpatient pain service. The primary outcome was pain intensity, measured with the visual analogic scale (VAS). Additional outcomes were symptoms evaluated using joint district-specific scales. The study also evaluated concentrations of 48 cytokines and chemokines involved in the balance pro-inflammation/anti-inflammation and tissue repair in the ACS. ResultsWe included 26 patients, mostly female (65.4%), with a median age of 63.5 years [IQR 58.25–73]. A median reduction of VAS of −3 cm [−5; −1.25] was observed 6 months after the first injection of ACS. The analysis showed a statistically significant difference between the values of VAS (p < .01; X2 = 69.6; df = 6, N = 26) at the different time points. No adverse events were observed or reported by patients during the entire study period. ConclusionsConditional autologous serum may be a feasible option for patients with chronic pain due to grade I-III osteoarthritis refractory to other treatments. These preliminary findings should be confirmed in studies with adequate design.

Ippolito, M., Spurio, G., Compagno, V., Rizzo, A., Di Simone, M., Corsale, A.M., et al. (2022). Autologous conditioned serum for chronic pain in patients with osteoarthritis: A feasibility observational study. BRITISH JOURNAL OF PAIN, 17(1), 103-111 [10.1177/20494637221134169].

Autologous conditioned serum for chronic pain in patients with osteoarthritis: A feasibility observational study

Ippolito, Mariachiara;Spurio, Giulia;Compagno, Viviana;Di Simone, Marta;Corsale, Anna Maria;Mazzola, Giuseppina;Giarratano, Antonino;Meraviglia, Serena;Cortegiani, Andrea
;
Alongi, Antonietta
2022-10-20

Abstract

BackgroundAutologous conditioned serum is a product of blood origin, with fragmented evidence of therapeutic properties in osteoarthritis chronic pain. This pilot observational prospective study aimed to evaluate the feasibility of a treatment with conditional autologous serum (ACS) in patients with severe chronic pain and grade I-III osteoarthritis and to describe its cytokine content. MethodsWe prospectively collected data on consecutive patients affected by osteoarthritis grade I to III and treated with four weekly injections of ACS at our outpatient pain service. The primary outcome was pain intensity, measured with the visual analogic scale (VAS). Additional outcomes were symptoms evaluated using joint district-specific scales. The study also evaluated concentrations of 48 cytokines and chemokines involved in the balance pro-inflammation/anti-inflammation and tissue repair in the ACS. ResultsWe included 26 patients, mostly female (65.4%), with a median age of 63.5 years [IQR 58.25–73]. A median reduction of VAS of −3 cm [−5; −1.25] was observed 6 months after the first injection of ACS. The analysis showed a statistically significant difference between the values of VAS (p < .01; X2 = 69.6; df = 6, N = 26) at the different time points. No adverse events were observed or reported by patients during the entire study period. ConclusionsConditional autologous serum may be a feasible option for patients with chronic pain due to grade I-III osteoarthritis refractory to other treatments. These preliminary findings should be confirmed in studies with adequate design.
20-ott-2022
Ippolito, M., Spurio, G., Compagno, V., Rizzo, A., Di Simone, M., Corsale, A.M., et al. (2022). Autologous conditioned serum for chronic pain in patients with osteoarthritis: A feasibility observational study. BRITISH JOURNAL OF PAIN, 17(1), 103-111 [10.1177/20494637221134169].
File in questo prodotto:
File Dimensione Formato  
Orthokine BJP.pdf

Solo gestori archvio

Tipologia: Post-print
Dimensione 618.66 kB
Formato Adobe PDF
618.66 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
corteggiani suppl.pdf

Solo gestori archvio

Descrizione: Supplementary material
Tipologia: Altro materiale (es. dati della ricerca)
Dimensione 364.11 kB
Formato Adobe PDF
364.11 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
20494637221134169.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 617.59 kB
Formato Adobe PDF
617.59 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/571947
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact